Yonsei Medical Journal

Yonsei Univ College Medicine (연세대학교의과대학)
권호 표지
DOI QR코드

DOI QR Code

Posaconazole Treatment in Korea: Single-Center Experience Over 5 Years

  • Lee, Hyo-Jin (Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • Kwon, Jae-Cheol (Division of Infectious Diseases, Department of Internal Medicine, National Health Insurance Corporation Ilsan Hospital) ;
  • Kim, Si-Hyun (Department of Life Sciences, Pohang University of Science and Technology) ;
  • Choi, Su-Mi (Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • Lee, Dong-Gun (Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • Park, Sun-Hee (Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • Choi, Jung-Hyun (Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • Yoo, Jin-Hong (Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • Cho, Byung-Sik (Catholic Blood and Marrow Transplantation Center, College of Medicine, The Catholic University of Korea) ;
  • Lee, Seok (Catholic Blood and Marrow Transplantation Center, College of Medicine, The Catholic University of Korea) ;
  • Kim, Hee-Je (Catholic Blood and Marrow Transplantation Center, College of Medicine, The Catholic University of Korea) ;
  • Min, Chang-Ki (Catholic Blood and Marrow Transplantation Center, College of Medicine, The Catholic University of Korea) ;
  • Lee, Jong-Wook (Catholic Blood and Marrow Transplantation Center, College of Medicine, The Catholic University of Korea) ;
  • Min, Woo-Sung (Catholic Blood and Marrow Transplantation Center, College of Medicine, The Catholic University of Korea)
  • Received : 2012.10.08
  • Accepted : 2012.11.14
  • Published : 2013.09.01
⟨ Previous Next ⟩

Abstract

Purpose: Posaconazole is a second-generation triazole with a broad spectrum. However, there is a lack of data to support a significant role for posaconazole in the treatment of invasive fungal infection (IFI), especially in Korea. Until recently, posaconazole was available only through the Korean Orphan Drug Center. This study was designed to review the use of posaconazole at a single-center in Korea. Materials and Methods: Data from patients who received posaconazole treatment at Catholic Blood and Marrow Transplantation Center were retrospectively reviewed between January 2007 and September 2012. Results: A total of 11 cases (3 males and 8 females, median age 52 years) received posaconazole. Five patients were given the drug for mucormycosis, two for invasive aspergillosis, and four for unspecified IFI for which galactomannan (GM) assays were negative. The treatment duration ranged from 4-250 days. Three patients received posaconazole for management refractory IFI, two for intolerance of previous antifungal therapy, and six for long-term maintenance treatment. The overall successful response rate to posaconazole was 55% (six of eleven patients). Five of eleven patients died during the study period. However, only one death was attributed to the progression of IFI. None of the patients discontinued posaconazole therapy due to adverse events. Conclusion: Posaconazole is an attractive oral antifungal agent for salvage treatment of IFI, particularly upon diagnosis of mucormycosis or in cases in which mucormycosis cannot be ruled out due to a negative GM.

Keywords

References

  1. Mullane K, Toor AA, Kalnicky C, Rodriguez T, Klein J, Stiff P. Posaconazole salvage therapy allows successful allogeneic hematopoietic stem cell transplantation in patients with refractory invasive mold infections. Transpl Infect Dis 2007;9:89-96. https://doi.org/10.1111/j.1399-3062.2007.00208.x
  2. Rachwalski EJ, Wieczorkiewicz JT, Scheetz MH. Posaconazole: an oral triazole with an extended spectrum of activity. Ann Pharmacother 2008;42:1429-38. https://doi.org/10.1345/aph.1L005
  3. Greenberg RN, Mullane K, van Burik JA, Raad I, Abzug MJ, Anstead G, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006;50:126-33. https://doi.org/10.1128/AAC.50.1.126-133.2006
  4. Nagappan V, Deresinski S. Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis 2007;45:1610-7. https://doi.org/10.1086/523576
  5. Morris MI. Posaconazole: a new oral antifungal agent with an expanded spectrum of activity. Am J Health Syst Pharm 2009;66: 225-36. https://doi.org/10.2146/ajhp070532
  6. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813-21. https://doi.org/10.1086/588660
  7. Segal BH, Herbrecht R, Stevens DA, Ostrosky-Zeichner L, Sobel J, Viscoli C, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 2008;47:674-83. https://doi.org/10.1086/590566
  8. Raad II, Hachem RY, Herbrecht R, Graybill JR, Hare R, Corcoran G, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006;42:1398-403. https://doi.org/10.1086/503425
  9. Lee DG, Kim SH, Kim SY, Kim CJ, Park WB, Song YG, et al. Evidence-based guidelines for empirical therapy of neutropenic fever in Korea. Korean J Intern Med 2011;26:220-52. https://doi.org/10.3904/kjim.2011.26.2.220
  10. Common terminology criteria for adverse events (CTCAE) v4.0. National Cancer Institute; 2009.
  11. Yoon YK, Kim MJ, Chung YG, Shin IY. Successful treatment of a case with rhino-orbital-cerebral mucormycosis by the combination of neurosurgical intervention and the sequential use of amphotericin B and posaconazole. J Korean Neurosurg Soc 2010;47:74-7. https://doi.org/10.3340/jkns.2010.47.1.74
  12. Kim WJ, Han SY, Nam YH, Kim JM, Ahn HB, Kim SJ, et al. A case of successful posaconazole salvage therapy for rhinocerebral mucormycosis after failure of amphotericin B. Korean J Med 2010;79:587-91.
  13. Alastruey-Izquierdo A, Castelli MV, Cuesta I, Zaragoza O, Monzón A, Mellado E, et al. In vitro activity of antifungals against Zygomycetes. Clin Microbiol Infect 2009;15 Suppl 5:71-6. https://doi.org/10.1111/j.1469-0691.2009.02984.x
  14. Cornely OA, Vehreschild JJ, Ruping MJ. Current experience in treating invasive zygomycosis with posaconazole. Clin Microbiol Infect 2009;15 Suppl 5:77-81. https://doi.org/10.1111/j.1469-0691.2009.02985.x
  15. Almyroudis NG, Sutton DA, Fothergill AW, Rinaldi MG, Kusne S. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother 2007;51:2587-90. https://doi.org/10.1128/AAC.00452-07
  16. Raad II, Hanna HA, Boktour M, Jiang Y, Torres HA, Afif C, et al. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin. Leukemia 2008;22:496-503. https://doi.org/10.1038/sj.leu.2405065
  17. Traunmuller F, Popovic M, Konz KH, Smolle-Juttner FM, Joukhadar C. Efficacy and safety of current drug therapies for invasive aspergillosis. Pharmacology 2011;88:213-24. https://doi.org/10.1159/000331860
  18. Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007;44:2-12. https://doi.org/10.1086/508774
  19. Greer ND. Posaconazole (Noxafil): a new triazole antifungal agent. Proc (Bayl Univ Med Cent) 2007;20:188-96.
  20. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006;42:e61-5. https://doi.org/10.1086/500212
  21. Krishnan-Natesan S, Manavathu EK, Alangaden GJ, Chandrasekar PH. A comparison of the fungicidal activity of amphotericin B and posaconazole against Zygomycetes in vitro. Diagn Microbiol Infect Dis 2009;63:361-4. https://doi.org/10.1016/j.diagmicrobio.2008.12.013
  22. Kontoyiannis DP. Invasive mycoses: strategies for effective management. Am J Med 2012;125(1 Suppl):S25-38. https://doi.org/10.1016/j.amjmed.2011.10.009
  23. Bhattacharya M, Rajeshwari K, Dhingra B. Posaconazole. J Postgrad Med 2010;56:163-7. https://doi.org/10.4103/0022-3859.65281
  24. Raad II, Graybill JR, Bustamante AB, Cornely OA, Gaona-Flores V, Afif C, et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 2006;42:1726-34. https://doi.org/10.1086/504328

Cited by

  1. Mucormycosis: A Case Report and Review of Literature vol.39, pp.1, 2013, https://doi.org/10.14476/jomp.2014.39.1.29
  2. Posaconazole Salvage Treatment for Invasive Fungal Infection vol.178, pp.3, 2013, https://doi.org/10.1007/s11046-014-9792-y
  3. Early diagnosis and successful management of oral mucormycosis in a hematopoietic stem cell transplant recipient: case report and literature review vol.24, pp.8, 2016, https://doi.org/10.1007/s00520-016-3170-x
  4. Utilization of posaconazole oral suspension or delayed‐released tablet salvage treatment for invasive fungal infection vol.59, pp.11, 2016, https://doi.org/10.1111/myc.12524
  5. Management of osteoarticular fungal infections in the setting of immunodeficiency vol.18, pp.5, 2020, https://doi.org/10.1080/14787210.2020.1748499
  6. Real-world assessment of the effectiveness of posaconazole for the prophylaxis and treatment of invasive fungal infections in hematological patients : A retrospective observational study vol.100, pp.30, 2013, https://doi.org/10.1097/md.0000000000026772